ES2147729T3 - Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano. - Google Patents

Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.

Info

Publication number
ES2147729T3
ES2147729T3 ES92906305T ES92906305T ES2147729T3 ES 2147729 T3 ES2147729 T3 ES 2147729T3 ES 92906305 T ES92906305 T ES 92906305T ES 92906305 T ES92906305 T ES 92906305T ES 2147729 T3 ES2147729 T3 ES 2147729T3
Authority
ES
Spain
Prior art keywords
growth factor
extracellular region
human platelets
polypeptides
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906305T
Other languages
English (en)
Inventor
Jaime A Escobedo
Lewis T Williams
David Wolf
James E Tomlinson
Larry J Fretto
Neill A Giese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
University of California Berkeley
University of California San Diego UCSD
Original Assignee
COR Therapeutics Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc, University of California Berkeley, University of California San Diego UCSD filed Critical COR Therapeutics Inc
Application granted granted Critical
Publication of ES2147729T3 publication Critical patent/ES2147729T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN CONSTRUCCIONES DEFINIDAS DE POLIPEPTIDOS RECEPTORES DE FACTOR DE CRECIMIENTO DERIVADOS DE PLAQUETAS HUMANAS. SE PRESENTAN LAS ESTRUCTURAS DE CAMPO DE REGION EXTRACELULAR SE IDENTIFICAN Y LAS MODIFICACION Y REDISPOSICIONES COMBINATORIAS DE LOS SEGMENTOS RECEPTORES. TANTO EL ENLACE CELULAR CON LAS FORMAS SOLUBLES DE SEGMENTOS MODIFICADOS SE HACEN DISPONIBLES, AL SER METODOS PARA ENSAYOS QUE LOS UTILIZAN, PERMITIENDO EL FILTRADO O LOS ANALOGOS DE LIGANDOS.
ES92906305T 1991-01-31 1992-01-28 Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano. Expired - Lifetime ES2147729T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65079391A 1991-01-31 1991-01-31

Publications (1)

Publication Number Publication Date
ES2147729T3 true ES2147729T3 (es) 2000-10-01

Family

ID=24610314

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906305T Expired - Lifetime ES2147729T3 (es) 1991-01-31 1992-01-28 Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.

Country Status (13)

Country Link
US (3) US5686572A (es)
EP (1) EP0584082B1 (es)
JP (1) JPH06507543A (es)
AT (1) ATE193553T1 (es)
AU (2) AU1411092A (es)
CA (1) CA2100559C (es)
DE (1) DE69231128T2 (es)
DK (1) DK0584082T3 (es)
ES (1) ES2147729T3 (es)
GR (1) GR3034267T3 (es)
IE (1) IE920317A1 (es)
NZ (1) NZ241480A (es)
WO (1) WO1992013867A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
EP0584082B1 (en) * 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
AU675924B2 (en) * 1991-12-02 1997-02-27 Cor Therapeutics, Inc. Methods for production of purified soluble type B and type Ahuman platelet-derived growth factor receptor fragments
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US20040002117A1 (en) * 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
ATE489108T1 (de) 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
ATE324444T1 (de) * 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
US6667173B2 (en) 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7595154B2 (en) * 2002-06-13 2009-09-29 Oregon Health And Science University Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
KR101246504B1 (ko) 2005-06-17 2013-03-26 임클론 엘엘씨 항－ＰＤＧＦＲα 항체
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CA2682390A1 (en) 2007-04-17 2008-10-30 Imclone Llc Pdgfr.beta.-specific inhibitors
WO2008142165A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
AU2008262384B9 (en) 2007-06-05 2014-11-27 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
ES2456296T3 (es) * 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
AU2011274363A1 (en) 2010-07-02 2013-01-24 Medimmune, Llc Antibody formulations
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
SI2968461T1 (sl) 2013-03-13 2023-01-31 Genzyme Corporation Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
EP4031164A4 (en) * 2019-09-17 2023-10-25 The Board Of Trustees Of The University Of Illinois MODIFIED RECEPTORS FOR HUMAN CYTOMEGALOVIRUS AND THEIR USES
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721983A1 (en) * 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
AU607306B2 (en) * 1988-02-02 1991-02-28 Regents Of The University Of California, The Human platelet-derived growth factor receptor
EP0456766B1 (en) * 1989-02-09 1999-04-28 The United States Of America TYPE oc PLATELET-DERIVED GROWTH FACTOR RECEPTOR GENE
IL97996A0 (en) * 1990-04-30 1992-06-21 Novo Nordisk As Hybrid cellular receptor
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
EP0584082B1 (en) * 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
AU675924B2 (en) * 1991-12-02 1997-02-27 Cor Therapeutics, Inc. Methods for production of purified soluble type B and type Ahuman platelet-derived growth factor receptor fragments
CA2124958C (en) * 1991-12-02 2007-02-13 Vanitha Ramakrishnan Inhibitory immunoglobulin polypeptides to human pdgf beta receptor

Also Published As

Publication number Publication date
AU1411092A (en) 1992-09-07
CA2100559A1 (en) 1992-08-01
US5891652A (en) 1999-04-06
US5872218A (en) 1999-02-16
CA2100559C (en) 2007-05-22
US5686572A (en) 1997-11-11
EP0584082A4 (en) 1994-08-24
ATE193553T1 (de) 2000-06-15
DE69231128T2 (de) 2001-02-15
GR3034267T3 (en) 2000-12-29
NZ241480A (en) 1993-09-27
WO1992013867A1 (en) 1992-08-20
DE69231128D1 (de) 2000-07-06
AU5580496A (en) 1996-09-19
EP0584082B1 (en) 2000-05-31
IE920317A1 (en) 1992-07-29
DK0584082T3 (da) 2000-10-16
AU709177B2 (en) 1999-08-26
JPH06507543A (ja) 1994-09-01
EP0584082A1 (en) 1994-03-02

Similar Documents

Publication Publication Date Title
MX9100628A (es) Compuestos peptidomimeticos de borolisina y procedimiento para su preparacion.
ES2128362T3 (es) Fragmentos de proteinas de prion.
ATE193553T1 (de) Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden
MX9204661A (es) Compuestos intermedios derivados de eter y procedimiento para su preparacion.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
MX9302917A (es) Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.
ATE41419T1 (de) Bismaleimide und daraus erhaltene prepregharze.
ES2122043T3 (es) Nuevos derivados sustituidos del pirazol, procedimientos para su preparacion y su empleo como herbicidas.
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
ES508525A0 (es) "procedimiento para el desencolado o desapresto de materiales de fibra de contenido celulosico".
AR016981A2 (es) Polipeptidos sinteticos
DE69027170D1 (de) Uracilderivate, ihre Herstellung und ihre Verwendung
ES8505539A1 (es) Procedimiento para la obtencion de derivados de alcohol bencilico con propiedades sebosupresoras
ATE188692T1 (de) Fibrinogenrezeptorantagonisten
NO900643D0 (no) Fremgangsmaate for fremstilling og anvendelse av 2,3,23-trihydroksi-urs-12-ener og deres derivater.
DE69021625D1 (de) Breitband-Koppelfeld mit deaktivierten Koppelpunkten zur Herstellung von Vermittlungswegen.
NO913096L (no) Fremgangsmaate for fremstilling av formlegemer av silisiuminnfiltrert silisiumkarbid.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
IT9003428A0 (it) Procedimento per la realizzazione di calzature e calzatura ottenuta con tale procedimento
DE59003312D1 (de) Verwendung von Diphenyletherderivaten zur Desikkation und Abszission von Pflanzenorganen.
ES2150034T3 (es) Empleo de las 2-aminotetralinas substituidas en 6,7 para la preparacion de composiciones farmaceuticas de utilidad para el tratamiento del choque septico, y composiciones farmaceuticas antipireticas y antiinflamatorias.
AR220140A1 (es) Procedimiento para la preparacion de derivados de 1-(2-metilfenil)-tetrahidro-s-triazin-2-tiono con utiles propiedades pesticidas
ES2101531T3 (es) Derivados de benzo(f)quinoxalinadiona, su preparacion y su utilizacion en medicamentos.
ES2134879T3 (es) Metalocenos que contienen compuestos de fluorenilo sustituidos en la posicion 9 y uso de los metalocenos.
DK447184A (da) Fremgangsmaade til fremstilling af kondenserede as-triazinderivater og isomere deraf, saaledes fremstillede derivater og disses anvendelse

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 584082

Country of ref document: ES